SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Since GcgRi co-treatment only reduced the Arg/ADMA increase we hypothesize that dapagliflozin via a glucagon-signaling dependent pathway improves vascular function through the NO-signaling pathway leading to improved vascular function. Increase in ketone levels might be a contributing factor in SGLT2i induced contractility increase and does not require glucagon signaling.
Authors
- Sven Göpel
- V. Sashi Gopaul (ORCID: https://orcid.org/0000-0002-0729-3331)
- Damilola D. Adingupu (ORCID: https://orcid.org/0000-0002-0312-2359)
- Rui‐Ping Xiao (ORCID: https://orcid.org/0000-0003-2448-409X)
- Christine Ahlström (ORCID: https://orcid.org/0009-0003-0575-2295)
- Rasmus Jansson‐Löfmark (ORCID: https://orcid.org/0000-0003-1773-197X)
- Margareta Behrendt (ORCID: https://orcid.org/0000-0003-3068-7627)
- Elizaveta Semenova (ORCID: https://orcid.org/0000-0002-8271-2575)
- Li‐Ming Gan (ORCID: https://orcid.org/0000-0003-2933-1404)
- Ann-Cathrine Jönsson-Rylander
- Russell Esterline
- Jue Wang (ORCID: https://orcid.org/0009-0007-6536-4242)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Peking University (CN)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Imperial College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2024-11-15
- DOI
- https://doi.org/10.1186/s12933-024-02491-w
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- AstraZeneca